Morgan Stanley raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $9 from $7 and keeps an Equal Weight rating on the shares following what the firm calls a “solid beat/raise” report. While the firm says it sees room for second half estimate upside, it adds that valuation has now gapped up to comps, “suggesting a period of digestion may be on the cards.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Strong Q1 Performance but Hold Rating Due to Valuation Concerns
- Adaptive Biotechnologies Reports Strong Earnings and Strategic Growth
- Apple reports earnings beat, China weighs trade talks with U.S.: Morning Buzz
- Positive Outlook for Adaptive Biotechnologies: Strong Revenue Growth and Strategic Initiatives Support Buy Rating
- Adaptive Biotechnologies Reports Strong Q1 2025 Growth